Midgard Science

Labs / CDMO: development & manufacturing

NA

Nitto Avecia

Milford, MA, United States · avecia.com

GMP · FDA registered

Nitto Avecia develops and manufactures oligonucleotide therapeutics for pharmaceutical companies, from preclinical work through commercial supply. It operates facilities in Milford, Massachusetts, and Cincinnati, Ohio, serving customers with development, manufacturing, analytical, and quality support.

They take quote requests through a form on their website with project details. Their quote form

What they offer

  • Preclinical Manufacturing

    Provides custom preclinical oligonucleotide manufacturing through the OliGrow® service for non-cGMP applications.

  • Analytical Development

    Develops, qualifies, and validates analytical methods for raw materials, intermediates, and final product, including support for ICH stability studies.

  • Process Development

    Develops and validates oligonucleotide processes and supports onboarding risk assessments, scale-up, specification development, and raw material qualification.

  • Drug Substance Manufacturing

    Manufactures oligonucleotide drug substance from preclinical quantities to commercial supply.

  • Process Performance Qualification

    Develops and executes PPQ programs for oligonucleotide manufacturing.

  • Quality Control/Stability

    Provides study design, comprehensive testing services, and sample storage conditions for quality control and stability work.

What they work on

Modalities
Oligonucleotide, Gene editing
Assays and studies
analytical method development, method transfer, method validation, stability studies, impurity testing, sequencing, environmental monitoring, raw material analysis, in-process analysis, final product analysis
Instruments and platforms
LC-ESI-MS/MS, HRAMS
Scale and capacity
batch sizes from 100 mg to 25 g, batches from a few mmol up to 1600 mmol, first 50 mg of preclinical material, hundreds of kilograms in commercial supply, multiple cGMP manufacturing trains, ISO8-qualified, HEPA-filtered manufacturing suites
Turnaround
fast turnaround times
Type
CRDMO
Sites
Milford, United States · Cincinnati, United States
Quality
FDA-inspected · GMP-compliant · cGMP requirements of 21 CFR Part 210 and · ICH Q7 · EU Current Good Manufacturing Practice f · FDA-registered facilities · Successful track record of FDA and QP in · Most recent FDA inspection in August 202 (Cincinnati facility)
Serves
global
Address
125 Fortune Boulevard Milford, MA 01757

Public records

FDA establishment
3000215431
FDA drug establishment
Nitto Denko Avecia Inc. source
Vice President of Business Development & Project Manag
Management Craig Dobbs on their site
FDA drug establishment registration
3000215431 · API MANUFACTURE source

Similar labs. Alcami, Minaris, Porton, WuXi STA

Found in a contract services directory. Listing built from avecia.com. Work here? Claim this listing.

Nitto Avecia · Midgard Science